LONDON (ShareCast) - (Sharecast News) - Syncona on Tuesday said its portfolio company Blue Earth Diagnostics had reported positive results from a study into prostate cancer diagnosis.


The study, conducted as a clinical experience in academic setting at the Technical University at Munich, used radiohybrid PSMA-targeted agent rhPSMA-7 in high-risk primary and recurrent prostate cancer.

Blue Earth bought rhPSMA-7 in 2018 to extend its position in prostate cancer imaging, including potential new areas of high unmet need, such as early stage primary prostate cancer patients, Syncona said in a statement.

A retrospective analysis of 58 patients with high risk primary prostate cancer indicated that 18F-rhPSMA-7 PET/CT demonstrated sensitivity of 72%, specificity of 93% and diagnostic accuracy 86%, when compared to histopathological findings.

"We are encouraged by these results, which provide further evidence to support the potential clinical utility of rhPSMA-7 in both high-risk primary and recurrent prostate cancer," said Sycona Investments chief executive Martin Murphy.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE